Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 10:26AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.56 Insider Own0.30% Shs Outstand150.41M Perf Week-0.44%
Market Cap2.71B Forward P/E- EPS next Y-0.56 Insider Trans0.00% Shs Float150.21M Perf Month-0.66%
Income-206.37M PEG- EPS next Q-0.08 Inst Own15.84% Short Float1.09% Perf Quarter75.49%
Sales257.57M P/S10.51 EPS this Y21.14% Inst Trans5.68% Short Ratio0.86 Perf Half Y164.65%
Book/sh0.36 P/B49.88 EPS next Y52.57% ROA-8.61% Short Interest1.63M Perf Year245.58%
Cash/sh4.98 P/C3.61 EPS next 5Y- ROE-185.77% 52W Range4.18 - 18.31 Perf YTD81.52%
Dividend Est.- P/FCF- EPS past 5Y-23.10% ROI-61.89% 52W High-1.83% Beta1.14
Dividend TTM- Quick Ratio2.84 Sales past 5Y67.37% Gross Margin71.12% 52W Low329.39% ATR (14)0.17
Dividend Ex-Date- Current Ratio3.08 EPS Y/Y TTM-20.26% Oper. Margin-105.16% RSI (14)56.16 Volatility0.65% 0.60%
Employees564 Debt/Eq5.26 Sales Y/Y TTM-11.00% Profit Margin-80.12% Recom2.56 Target Price16.48
Option/ShortYes / Yes LT Debt/Eq5.15 EPS Q/Q-86.66% Payout- Rel Volume0.09 Prev Close18.04
Sales Surprise0.20% EPS Surprise176.72% Sales Q/Q-23.75% EarningsMar 13 AMC Avg Volume1.90M Price17.97
SMA20-0.65% SMA500.94% SMA20072.39% Trades Volume32,935 Change-0.39%
Date Action Analyst Rating Change Price Target Change
Mar-14-24Downgrade Wells Fargo Overweight → Equal Weight
Jan-16-24Downgrade Morgan Stanley Overweight → Equal-Weight $9.20 → $10.40
Oct-13-23Upgrade Morgan Stanley Underweight → Overweight $3.70 → $9.20
Sep-15-23Upgrade Goldman Sell → Neutral $3.50 → $9.25
Jul-17-23Upgrade Deutsche Bank Sell → Hold
Jun-16-23Upgrade JP Morgan Underweight → Overweight $3.30 → $10
Jun-16-23Initiated Wells Fargo Overweight $17
May-31-23Initiated UBS Buy
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight
Dec-16-22Downgrade Goldman Neutral → Sell
Apr-12-24 06:26AM
Apr-11-24 09:00AM
Apr-03-24 08:48AM
Mar-30-24 03:52PM
Mar-22-24 02:50AM
10:37AM Loading…
Mar-15-24 10:37AM
Mar-13-24 04:02PM
Mar-11-24 12:44PM
Mar-07-24 04:15PM
Mar-05-24 02:56AM
Mar-04-24 12:00PM
Feb-16-24 03:55AM
Feb-15-24 12:00PM
Feb-06-24 10:29AM
Feb-05-24 05:44PM
05:30PM Loading…
Jan-30-24 03:15AM
Jan-08-24 02:20AM
Dec-10-23 07:31PM
Nov-21-23 09:09AM
Nov-20-23 04:50PM
Nov-17-23 09:59AM
Nov-15-23 04:01PM
04:20PM Loading…
Nov-09-23 04:20PM
Nov-02-23 09:45AM
Oct-25-23 05:10AM
Sep-15-23 09:32AM
Sep-12-23 04:20PM
Aug-09-23 04:01PM
Jun-26-23 04:00PM
May-03-23 04:01PM
Apr-27-23 04:20PM
Apr-17-23 03:32AM
Apr-16-23 03:01PM
Mar-19-23 11:15PM
Mar-15-23 04:03PM
Mar-09-23 04:20PM
Mar-02-23 04:00AM
Jan-09-23 01:20AM
Jan-05-23 06:00AM
Dec-07-22 09:48AM
Nov-28-22 04:30PM
Nov-19-22 01:45AM
Nov-16-22 04:01PM
Nov-14-22 04:11PM
Nov-10-22 04:30PM
Nov-08-22 12:45AM
Nov-03-22 09:25AM
Oct-28-22 11:14AM
Oct-27-22 04:20PM
Oct-21-22 06:00AM
Sep-29-22 09:21AM
Aug-06-22 02:00PM
Aug-03-22 04:01PM
Jul-28-22 04:20PM
Jul-26-22 05:40AM
Jun-15-22 08:30AM
Jun-14-22 04:57PM
Jun-10-22 03:15AM
May-18-22 08:05PM
May-12-22 10:45AM
May-05-22 08:30PM
May-04-22 04:01PM
Apr-28-22 04:45PM
Apr-12-22 09:55AM
Mar-23-22 07:05AM
Mar-22-22 04:45PM
Mar-16-22 04:07PM
Mar-15-22 04:40PM
Mar-10-22 04:35PM
Jan-24-22 04:20PM
Jan-18-22 01:00AM
Jan-10-22 02:20AM
Dec-12-21 09:00AM
Dec-11-21 12:00PM
Nov-29-21 04:15PM
Nov-11-21 08:00PM
Nov-09-21 04:20PM
Nov-05-21 11:03AM
Nov-04-21 04:20PM
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.